Prostate cancer is a leading cause of male cancer deaths worldwide, with one man in every seven likely to contract the disease during his lifetime. As late-stage prostate cancer remains a fatal disease resistant to conventional treatment, the need for effective new therapies is dire. Dr Douglas McNeel, a Professor of Medicine in the Haemato-Oncology Division of the University of Wisconsin’s Carbone Cancer Centre, has been working to meet this need. His team’s goal is to identify specific proteins of the prostate that could be used to generate anti-tumour vaccines, and then evaluate the best means to deploy these vaccines to treat prostate cancers.
Read more...
